Compare Stocks

→ Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HOOK Hookipa Pharma	$0.89 +11.2%	$0.74	$0.41 ▼ $2.05	$88.39M	1.02	740,199 shs	2.89 million shs
KZR Kezar Life Sciences	$0.80 +1.3%	$0.89	$0.67 ▼ $3.13	$58.60M	0.47	690,655 shs	496,282 shs
LRMR Larimar Therapeutics	$6.44 +1.7%	$8.87	$2.18 ▼ $13.68	$410.87M	0.93	549,200 shs	144,231 shs
ORMP Oramed Pharmaceuticals	$2.46 +7.0%	$2.83	$1.67 ▼ $5.25	$99.68M	1.81	164,756 shs	84,471 shs

7 Stocks to Own Before the 2024 Election

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HOOK Hookipa Pharma	-5.16%	+5.39%	+12.11%	+15.03%	-20.19%
KZR Kezar Life Sciences	-1.42%	+0.30%	-11.62%	-4.76%	-66.67%
LRMR Larimar Therapeutics	-2.01%	-0.78%	-12.08%	+29.45%	+40.04%
ORMP Oramed Pharmaceuticals	-2.95%	+4.55%	-15.44%	-0.86%	+3.14%

Protect Yourself While There’s Still Time … (Ad)

The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.

4 simple steps to protect your privacy and money before it’s too late.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
HOOK Hookipa Pharma	2.976 of 5 stars	3.5	3.0	0.0	0.0	2.9	1.7	1.3
KZR Kezar Life Sciences	3.5193 of 5 stars	3.2	1.0	0.0	4.6	0.6	1.7	1.3
LRMR Larimar Therapeutics	2.2489 of 5 stars	4.5	1.0	0.0	0.0	0.6	3.3	0.0
ORMP Oramed Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HOOK Hookipa Pharma	3.00	Buy	$4.67	422.41% Upside
KZR Kezar Life Sciences	2.33	Hold	$11.00	1,266.63% Upside
LRMR Larimar Therapeutics	3.00	Buy	$18.50	187.27% Upside
ORMP Oramed Pharmaceuticals	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest LRMR, HOOK, KZR, and ORMP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/26/2024	HOOK Hookipa Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$6.50 ➝ $5.00
4/3/2024	LRMR Larimar Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
4/3/2024	LRMR Larimar Therapeutics	SVB Leerink Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$25.00
3/25/2024	HOOK Hookipa Pharma	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$5.00
3/25/2024	HOOK Hookipa Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.50
3/15/2024	KZR Kezar Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
3/15/2024	LRMR Larimar Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$25.00
2/20/2024	LRMR Larimar Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
2/13/2024	LRMR Larimar Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$4.50 ➝ $10.00
2/13/2024	LRMR Larimar Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$17.00 ➝ $25.00
1/30/2024	HOOK Hookipa Pharma	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$6.00 ➝ $5.00

(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HOOK Hookipa Pharma	$20.13M	4.39	N/A	N/A	$0.91 per share	0.98
KZR Kezar Life Sciences	$7M	8.37	N/A	N/A	$2.58 per share	0.31
LRMR Larimar Therapeutics	N/A	N/A	N/A	N/A	$1.86 per share	N/A
ORMP Oramed Pharmaceuticals	$1.34M	74.39	N/A	N/A	$4.04 per share	0.61

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HOOK Hookipa Pharma	-$81.58M	-$0.88	N/A	N/A	N/A	-405.28%	-72.30%	-40.51%	5/9/2024 (Estimated)
KZR Kezar Life Sciences	-$101.87M	-$1.41	N/A	N/A	N/A	N/A	-43.08%	-37.59%	5/9/2024 (Estimated)
LRMR Larimar Therapeutics	-$36.95M	-$0.85	N/A	N/A	N/A	N/A	-38.83%	-34.33%	5/20/2024 (Estimated)
ORMP Oramed Pharmaceuticals	$5.53M	$0.14	17.57	∞	N/A	N/A	-7.15%	-5.70%	5/9/2024 (Estimated)

Latest LRMR, HOOK, KZR, and ORMP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
3/22/2024	Q4 2023	HOOK Hookipa Pharma	-$0.20	-$0.11	+$0.09	N/A	$3.60 million	$7.41 million
3/14/2024	Q4 2023	KZR Kezar Life Sciences	-$0.39	-$0.35	+$0.04	-$0.26	N/A	N/A
3/14/2024	Q4 2023	LRMR Larimar Therapeutics	-$0.25	-$0.30	-$0.05	-$0.30	N/A	N/A
3/6/2024	Q4 2023	ORMP Oramed Pharmaceuticals	-$0.12	-$0.08	+$0.04	-$0.49	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
HOOK Hookipa Pharma	N/A	N/A	N/A	N/A	N/A
KZR Kezar Life Sciences	N/A	N/A	N/A	N/A	N/A
LRMR Larimar Therapeutics	N/A	N/A	N/A	N/A	N/A
ORMP Oramed Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HOOK Hookipa Pharma	N/A	3.50	3.50
KZR Kezar Life Sciences	0.05	11.66	11.66
LRMR Larimar Therapeutics	N/A	9.49	9.49
ORMP Oramed Pharmaceuticals	N/A	3.06	3.06

Ownership

Institutional Ownership

Company	Institutional Ownership
HOOK Hookipa Pharma	63.88%
KZR Kezar Life Sciences	67.90%
LRMR Larimar Therapeutics	91.92%
ORMP Oramed Pharmaceuticals	12.73%

Insider Ownership

Company	Insider Ownership
HOOK Hookipa Pharma	5.82%
KZR Kezar Life Sciences	7.90%
LRMR Larimar Therapeutics	4.30%
ORMP Oramed Pharmaceuticals	12.00%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
HOOK Hookipa Pharma	56	98.95 million	93.19 million	Optionable
KZR Kezar Life Sciences	58	72.80 million	67.05 million	Not Optionable
LRMR Larimar Therapeutics	42	63.80 million	61.06 million	Optionable
ORMP Oramed Pharmaceuticals	12	40.52 million	35.66 million	Optionable

LRMR, HOOK, KZR, and ORMP Headlines

Source	Headline
	BML Capital Management LLC Has $2.91 Million Stake in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) marketbeat.com - April 24 at 5:18 AM
	Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Sees Large Growth in Short Interest marketbeat.com - April 15 at 4:39 PM
	ORMP Apr 2024 2.500 put finance.yahoo.com - March 16 at 1:52 AM
	Oramed Pharmaceuticals Full Year 2023 Earnings: Beats Expectations finance.yahoo.com - March 9 at 2:05 PM
	Oramed to reinitiate pivotal type 2 diabetes trial after Phase III flop msn.com - February 21 at 6:04 PM
	Oramed Pharmaceuticals Inc.: Oramed Letter to Shareholders finanznachrichten.de - February 20 at 4:02 PM
	Oramed Letter to Shareholders prnewswire.com - February 20 at 8:30 AM
	ORMP: Multiple Potential Applications for Proprietary Oral Protein Delivery Platform finance.yahoo.com - January 24 at 1:21 PM
	Oramed Pharmaceuticals (ORMP) Price Target Increased by 36.51% to 4.39 msn.com - November 28 at 8:11 PM
	Oramed Pharmaceuticals (ORMP) Price Target Increased by 57.50% to 3.21 msn.com - November 2 at 10:07 AM
	Oramed Pharmaceuticals (NASDAQ:ORMP) investors are sitting on a loss of 63% if they invested a year ago finance.yahoo.com - October 6 at 1:58 PM
	Oramed Announces $101,875,000 Short-Term Senior Secured Note Transaction with Scilex Holding Company finance.yahoo.com - September 21 at 7:02 PM
	Other OTC Pharmaceuticals - Indonesia statista.com - September 19 at 1:52 PM
	Scilex Holding Company Enters into Non-Binding Term Sheets for the Purchase of all of the ... bakersfield.com - September 15 at 10:14 AM
	Oramed and HTIT to form joint venture for oral drug products pharmaceutical-technology.com - August 3 at 7:38 AM
	Oramed Signs Term Sheet with HTIT to Create a Joint Venture to Advance Oral Drug Delivery Technology Globally finance.yahoo.com - August 2 at 11:08 AM
	Oramed Pharmaceuticals, Inc. jp.reuters.com - July 25 at 12:37 PM
	Taking a Closer Look At Oramed Pharmaceuticals Inc. (ORMP) Following Its Recent Trade knoxdaily.com - July 4 at 8:28 PM
	Investing in Oramed Pharmaceuticals Inc. (ORMP): What You Must Know knoxdaily.com - June 26 at 9:08 AM
	Oramed Pharmaceuticals Inc. (ORMP) may enjoy gains as insiders got busy in the recent days knoxdaily.com - June 20 at 3:22 PM
	Oramed to Present at the 83rd American Diabetes Association Conference finance.yahoo.com - June 20 at 10:21 AM
	Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans finance.yahoo.com - June 17 at 2:50 PM
	ORMP’s short interest surges to 0.92 million shares knoxdaily.com - June 16 at 6:13 PM
	ORMP Stock Sees Surge of Approximately 0.25% in Last Five Days knoxdaily.com - June 8 at 8:08 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Hookipa Pharma

NASDAQ:HOOK

HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.

Kezar Life Sciences

NASDAQ:KZR

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Larimar Therapeutics

NASDAQ:LRMR

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.

Oramed Pharmaceuticals

NASDAQ:ORMP

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial